Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2019
Event: Entry into a Material Definitive Agreement for a firm commitment underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Specific figures include:
- Shares to be Sold: 6,875,000 shares of Common Stock (Firm Shares).
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 1,031,250 shares exercisable for 30 days.
- Offering Price: $4.00 per share to the public.
- Expected Gross Proceeds: Approximately $27.5 million (excluding underwriting discounts, commissions, and expenses; assuming no exercise of the option).
- Estimated Offering Expenses: $220,000 total, comprising $150,000 in legal fees, $50,000 in accountants' fees, $15,000 in miscellaneous expenses, and $5,000 in transfer agent fees.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement with Cantor Fitzgerald & Co. (lead book-running manager), Oppenheimer & Co. Inc., H.C. Wainwright & Co., and Roth Capital Partners. The transaction is expected to close on May 2, 2019, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to an effective "shelf" registration statement on Form S-3 filed in July 2018. The filing includes a standard disclaimer that representations and warranties in the Underwriting Agreement are for the benefit of the contracting parties and should not be relied upon by investors as characterizations of the actual state of facts.
Risks and Contingencies: The closing of the offering is contingent upon the satisfaction of customary closing conditions. The filing notes that information concerning representations and warranties may change after the date of the agreement.
Investor Verification Checklist
- Verify the final closing date of the offering (expected May 2, 2019) and whether the over-allotment option was exercised.
- Review the final prospectus supplement (expected to be filed May 1, 2019) for the exact underwriting discounts and commissions to determine net proceeds.
- Confirm the use of proceeds as detailed in the final prospectus supplement.
- Check subsequent filings for any updates on the company's cash position following the capital raise.